Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease
Authors' conclusion
Ezetimibe did not reduce the UACR or kidney-PF on top of modern T2D management. However, kidney-PF was reduced with ezetimibe in participants with high baseline kidney-PF.
Study context
- Population
- Individuals with T2D and early CKD (urine albumin creatinine ratio (UACR) ≥30 mg/g); mean age 67 ± 7 years, BMI 31 ± 4 kg/m², 84% men; mean eGFR 76 ± 22 mL/min/1.73m2; median UACR 95 (41–297) mg/g; median kidney-PF 1.0% (0.3%-2.1%)
- Participants
- 49 individuals
- Comparison
- Ezetimibe 10 mg once daily vs placebo for 16 weeks
- Ezetimiben = 25
- Placebon = 24reference
- Primary endpoint
- UACR and kidney parenchyma fat content (kidney-PF, by magnetic resonance spectroscopy)
- Follow-up
- 16 weeks
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
Each group vs placeboEstimate (95% CI)
Ezetimibe
mean change in UACR −3 %(−28%-31%)
Ezetimibe
mean change in kidney-PF −38 %(−66%-14%)
Further findings
| Outcome | Estimate | |
|---|---|---|
| Kidney-PF and UACR in participants with baseline kidney-PF above the medianEzetimibevs PlaceboSignificant reduction | mean change in kidney-PF −60 % (CI −84%--3%) | |
| Kidney-PF and UACR in participants with baseline kidney-PF above the medianEzetimibevs Placebo | mean change in UACR −28 % (CI −54%-15%) | |
| −100−50050Difference, % (linear scale) |
Original publication
Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. Published 6 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →